FilingSEC EDGAR8-K
Fennec Pharmaceuticals Reports Positive Phase 2 Results for PEDMARK in Japan
· SEC accepted
StagePhase 2 Results
Filing content
Fennec Pharmaceuticals announced positive results from its Phase 2 clinical study of PEDMARK in Japan, demonstrating significant hearing protection without interference with cisplatin antitumor activity.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…